1 / 93

Presented by: Date: Location:

Childhood vaccines at work in Canada. Presented by: Date: Location:. Presentation overview. The case for immunization Vaccine safety Vaccines in Canada Myths, facts and commonly asked questions Public policy Resources. © 2010 Canadian Paediatric Society I www.cps.ca. Sources of information.

frey
Download Presentation

Presented by: Date: Location:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Childhood vaccines at work in Canada Presented by:Date:Location:

  2. Presentation overview The case for immunization Vaccine safetyVaccines in CanadaMyths, facts and commonly asked questionsPublic policyResources © 2010 Canadian Paediatric Society I www.cps.ca

  3. Sources of information Based on Your Child’s Best Shot: A parent’s guide to vaccination (3rd edition, 2006)For updates including position statements from the CPS Infectious Diseases and Immunization Committee and current information for parents, visit the CPS websites: www.cps.ca and www.caringforkids.cps.ca Reviewed by the CPS Infectious Diseases and Immunization Committee. Lead reviewers: Dr. Bob Bartolussi and Dr. Dorothy Moore. © 2010 Canadian Paediatric Society I www.cps.ca

  4. The case for immunization © 2010 Canadian Paediatric Society I www.cps.ca

  5. Why we immunize • Vaccines save lives: A public health success story • Vaccines are safe and effective: The diseases they prevent can cause permanent disability or even death • It’s a small world: Travel can spread rare diseases quickly • Many vaccine-preventable diseases have no effective treatments • For some diseases, like tetanus, infection does not produce immunity: Vaccines produce immunity … Last, but not least … © 2010 Canadian Paediatric Society I www.cps.ca

  6. …Vaccines protect everyone • Directly: the person vaccinated, and • Indirectly: people who are vulnerable to disease, eg.,babies, children, the elderly, people with a weak immune system • Vaccines keep communities healthier: children in school, parents working, people interacting normally © 2010 Canadian Paediatric Society I www.cps.ca

  7. How vaccines work Immunology 101 • Bacteria and viruses have unique proteins and polysaccharides (complex sugars) on their surfaces called antigens • Immune system targets antigens using antibodies and lymphocytes • Lymphocytes (a type of white blood cell): include B-cells, T-cells and memory cells • Memory cells enable the immune system to recognize germs it has seen before, creating immune memory © 2010 Canadian Paediatric Society I www.cps.ca

  8. Immunity • Long-lasting immunity depends on memory cells.Immune memory is the ability the immune system acquires to identify the presence of a germ and destroy it • Two ways to achieve immunity: Natural infection or immunization • – Natural infection causes illness and can lead to complications, • permanent damage, even death • – Vaccines protect without causing severe illness © 2010 Canadian Paediatric Society I www.cps.ca

  9. Immunology of vaccines Types of vaccines © 2010 Canadian Paediatric Society I www.cps.ca

  10. Vaccine success in Canada © 2010 Canadian Paediatric Society I www.cps.ca

  11. Vaccine success in Canada (cont’d) © 2010 Canadian Paediatric Society I www.cps.ca

  12. Risks and benefits of vaccines © 2010 Canadian Paediatric Society I www.cps.ca

  13. Risks and benefits of vaccines (cont’d) © 2010 Canadian Paediatric Society I www.cps.ca

  14. Vaccine success stories • Smallpox has been eradicated. No cases anywhere in the world since 1979. Children are no longer vaccinated against smallpox • Paralytic polio eliminated from most of the world. Today, endemic in only four countries: Afghanistan, India, Nigeria, Pakistan – Cases dropped from 350,000 in 1988 to 1606 in 2009 – Recent outbreaks in former Soviet republics of Tajikistan, Uzbekistan – Tocompletely eradicate polio, all children must be vaccinated © 2010 Canadian Paediatric Society I www.cps.ca

  15. Why we (still) immunize • When vaccination rates decline, rates of disease increase • Example: In the late 1980s, former Soviet Union states saw vaccine supplies disrupted, collapse of their public health system and socioeconomic instability • Result: decrease in childhood immunization rates • Diphtheria epidemic followed: more than 150,000 cases and more than 4,000 deaths in the newly independent and Baltic states • Mass vaccination program eventually controlled the epidemic • Lesson: Complacency can be fatal © 2010 Canadian Paediatric Society I www.cps.ca

  16. Why outbreaks (still) occur • Outbreaks occur for different reasons, such as: • Public doubt: In the early 2000s, a flawed autism/MMR study in the U.K. led to decline in measles vaccination • – Results: Increase in local measles infection rates and deaths, and • spread of measles to other countries • – Lesson: Vaccination must continue to prevent disease outbreaks • Travel: Measles and mumps have been introduced into Canada by travellers, causing local outbreaks • 2008: Polio spread by travellers from the 4 countries where it remains endemic to 20 others • – Lesson: It’s a small world! Travel can spread a rare disease very • quickly © 2010 Canadian Paediatric Society I www.cps.ca

  17. Why outbreaks (still) occur (cont’d) • Waning immunity: Large mumps outbreak in 2007-08. Started in Nova Scotia, spread to New Brunswick and Alberta, with sporadic cases elsewhere • Mainly affected 20 to 29-year-olds in school settings • Prompted recommendation for a second dose of vaccine for high school, college/university students who had received only one dose in early childhood • Lesson: There may be a need for a second “booster” dose of mumps vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  18. Vaccine safety © 2010 Canadian Paediatric Society I www.cps.ca

  19. How vaccines are approved for use in Canada • The Biologics and Genetic Therapies Directorate (BGTD), Health Canada, reviews and approves all vaccines for human use in Canada • To be approved, vaccine providers must meet acceptable standards of safety, quality (efficacy) • Production: All aspects of production are supervised by the BGTD • Safety: BGTD does independent lab testing to evaluate safety and efficacy of early batches of vaccine • Quality: Specified by the BGTD, and repeatedly tested by lot sampling before and after vaccine is released for sale © 2010 Canadian Paediatric Society I www.cps.ca

  20. Recommendations for vaccine use • NACI: National Advisory Committee on Immunization makes recommendations to the Chief Public Health Officer • CIC: Canadian Immunization Committee assesses NACI recommendations and advises on operational plans • Provinces/territories use NACI and CIC recommendations to develop immunization programs • NACI’s Canadian Immunization Guide: Web-based guidelines from the Public Health Agency of Canada,published every 4 years (most recent edition 2010), at www.phac-aspc.gc.ca • Canadian Paediatric Society: Infectious Diseases and Immunization Committee’s position statements, at www.cps.ca © 2010 Canadian Paediatric Society I www.cps.ca

  21. Monitoring vaccine safety • Adverse events: Health effects occurring after immunization that may or may not be related to the vaccine • Mild adverse events, such as fever and swelling at the injection site, are common. More serious reactions are rare • Post-marketing surveillance of adverse events: The system for reporting and reviewing adverse events once a vaccine has been approved for use • Information gets to the Public Health Agency of Canada through doctors and nurses reporting to health officials • Doctors and nurses providing vaccines should know the local procedure for reporting vaccine adverse events to public health © 2010 Canadian Paediatric Society I www.cps.ca

  22. Entities involved in monitoring vaccine safety • Canadian Adverse Events Following Immunizations Surveillance System (CAEFISS): Receives reports fromdoctors, nurses • Advisory Committee on Causality Assessment (ACCA): Reviews all reported cases of serious adverse events • IMPACT: Immunization Monitoring Program, ACTive • The Vaccine Adverse Event Reporting System (VAERS): Post-marketing safety surveillance program in the U.S. • Institute of Medicine (IOM, U.S.): Immunization Safety Review Committee • GACVS (WHO): Global Advisory Committee on Vaccine Safety © 2010 Canadian Paediatric Society I www.cps.ca

  23. Vaccines in Canada © 2010 Canadian Paediatric Society I www.cps.ca

  24. Routine childhood vaccines • Pneumococcal vaccine: Protects against bacterial infections caused by Streptococcuspneumoniae,including meningitis, pneumonia, and ear infections • Meningococcal vaccine: Protects against bacterial infections caused by Neisseria meningitidis, including meningitis and septicemia, a serious blood infection • HPV vaccine: Protects against human papillomavirus types that cause cervical/vaginal cancer and genital warts • Rotavirus vaccine: Prevents rotavirus diarrhea • 5-in-1 (DTaP-IPV-Hib): Protects against diphtheria, tetanus, pertussis, polio, and bacterial infections caused by Hib (Haemophilus influenzae type b), including meningitis (a brain infection), and other serious infections • MMR: Protects against measles, mumps, and rubella • Hepatitis B vaccine • Varicella (chickenpox) vaccine • Seasonal influenza (“flu”) vaccine • Tdap: Tetanus, diphtheria and pertussis booster for teens and adults © 2010 Canadian Paediatric Society I www.cps.ca

  25. Additional vaccines or a “catch-up” schedule • Children with certain chronic conditions or who travel outside of North America may require additional vaccines • Children new to Canada may not have received vaccines which are routine here • Children who move within Canada may miss a dose of vaccine because schedules are not uniform across the country © 2010 Canadian Paediatric Society I www.cps.ca

  26. Contraindications to vaccination • Anaphylactic or other serious allergic reaction after receiving a vaccine is a contraindication to further doses of that vaccine • People with certain immune system disorders should not be given live vaccines (eg., measles, mumps, rubella, varicella, oral typhoid) • Avoid live vaccines during pregnancy, except when expected benefits to mother and baby outweigh risk © 2010 Canadian Paediatric Society I www.cps.ca

  27. Precautions • Delay giving vaccine if child has: • Moderate to severe illness • People treated with blood products should not get a live vaccine (eg., measles, mumps, rubella, varicella) for 3 months or more. Depending on the blood product and dose received, these vaccines may not work • Don’t delay vaccination because of minor illness (eg., a cough or cold, with or without fever). © 2010 Canadian Paediatric Society I www.cps.ca

  28. Diphtheria • Caused by a toxin made by bacteria that infect the nose, throat or skin • Can cause breathing problems, heart failure, nerve damage, kidney failure • About 1 person in 10 dies • Spread by close, direct contact withdroplets from a cough or sneeze • Before 1900, one of the main causes of childhood death. An estimated 12,000 cases/year in Canada, with 100 deaths • 1924: 9,000 cases in Canada • Routine immunization of Canadian children after 1930 • Since 1983:  5 cases/year, no deaths © 2010 Canadian Paediatric Society I www.cps.ca

  29. Diphtheria vaccine • Inactivated bacterial toxin • Given with tetanus, acellular pertussis, polio and Hib vaccines as 5-in-1 • Also given with tetanus and pertussis as a booster in adolescence • Also given with tetanus as a booster—recommended every 10 years for adults • Common local reactions: redness, swelling, pain and tenderness at the injection site • Only contraindication: anaphylactic or other serious allergic reaction to a previous dose of the vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  30. Tetanus • Caused by a toxin made by bacteria that block normal control of nerve reflexes in the spinal cord: also known as “lockjaw” • Not contagious: Spread through spores (seed-like cells) in the environment, especially contaminated soil and dust • Before vaccine: 60-75 cases/year in Canada, with 40-50 deaths • Routine immunization began in 1944 • Today  2 cases/year in Canada • Since tetanus spores are in the environment, vaccination is the only means of prevention • Tetanus infection does not produce immunity to tetanus • In countries without vaccination, tetanus still kills © 2010 Canadian Paediatric Society I www.cps.ca

  31. Tetanus vaccine • Inactivated bacterial toxin • Most often given with diphtheria, acellular pertussis, polio and Hib vaccines as 5-in-1 • Also given with diphtheria and pertussis as a booster in adolescence • Also given with diphtheria as a booster—recommended every 10 years for adults • Common local reactions: redness, swelling, pain and tenderness at the injection site • Only contraindication: an anaphylactic or other serious allergic reaction to a previous dose of the vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  32. Pertussis • Respiratory infection caused by bacteria: “whooping cough” • Causes severe coughing spells followed by a “whoop” sound • Lasts 6 to 12 weeks • 20-30% of infants with pertussis will be hospitalized • 1 in 400 infants will have brain damage • Very contagious: Spread by close, direct contact withdroplets from a cough or sneeze • Before vaccine: 30,000-50,000 cases/year with 50-100 deaths • Today: 3,000 cases in Canada, with about 5 deaths each year • Recent years: increasing number of cases in teens, young adults. Pertussis still a common cause of chronic cough (> 2 weeks) in teens and adults © 2010 Canadian Paediatric Society I www.cps.ca

  33. Pertussis vaccine • Whole-cell vaccine introduced in Canada in 1943 • Acellularpertussis replaced whole-cell vaccine in 1997 • Purified bacterial proteins: fewer side effects • Given with diphtheria, tetanus, polio and Hib vaccines as 5-in-1 • Also given to older children, teens and adults as a booster, combined with Td • Immunizing parents, adults working with children protects babies too young to be fully immunized • Does not prevent infection in everyone but effective in reducing severity of illness and the risk of complications • Minor local side effects are common • Only contraindication: anaphylactic or other serious allergic reaction to a previous dose of the vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  34. Polio • Caused by poliovirus • Before 1955, a common infection in Canada • Most infections asymptomatic (no symptoms) or mild, but 1-5% cause meningitis and 1%, paralytic polio • Virus in throat and feces of people who are infected: spreads by close direct contact with throat secretions and indirect contact (eg., contaminated hands, water, food) • 1959: last epidemic in Canada, with 2,000 cases of paralytic polio • Children ages 5 to 9 years the most affected. • 1989: last case of paralytic polio due to poliovirus in Canada • 2008: still seen regularly in 4 countries, and can be spread by travellers © 2010 Canadian Paediatric Society I www.cps.ca

  35. Polio vaccine • IPV (inactivated polio vaccine): killed, intact virus • Given with diphtheria, tetanus, pertussis and Hib vaccines as 5-in-1 • OPV (oral polio vaccine): live, attenuated virus. Not used in Canada since 1997-98, but still used in many countries • Side effects of IPV are rare • Effective and long-lasting: After 3 doses, 100% of infants develop antibodies against all 3 types of poliovirus • Only contraindication to IPV: an anaphylactic or other serious allergic reaction to a previous dose of the vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  36. Haemophilusinfluenzae type B (Hib) • Not to be confused with seasonal influenza or “flu” • Young children most at risk • Until 1985, the most common cause of bacterial meningitis in Canada: 1,500 cases/year in children  5 years old • Another 1,500 cases/year with serious infections (eg., of the blood, epiglottis, lungs, joints, bones and skin) • Meningitis: infection of the fluid and membranes covering the brain and spinal cord • Without treatment, all children with Hib meningitis die • Complications from Hib meningitis: brain damage, developmental delay, speech and language disorders, deafness • Not highly contagious: Hib bacteria in mouth, nose secretions spread by close, prolonged exposure or contact with droplets from a cough or sneeze A recent success story 1986: vaccine approved for use in Canada Since 2000: 5-16 cases/ yearof invasive Hib disease in children Hib disease is disappearing from every country with routine immunization for infants © 2010 Canadian Paediatric Society I www.cps.ca

  37. Hib vaccine • Purified bacterial polysaccharide linked to a protein carrier, such as diphtheria or tetanus toxoid • Given with diphtheria, tetanus, pertussis and polio vaccines as 5-in-1 • Protects child against Hib and helps decrease spread among children generally • Local redness and pain in 5-15% of infants • Only contraindication: anaphylactic or other serious allergic reaction to a previous dose of the vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  38. Pneumococcal disease • Streptococcus pneumoniae: most common cause of meningitis and other invasive, serious bacterial infections in children in Canada, especially in children < 2 years of age • Older children, teens and adults with certain chronic conditions are also at higher risk • Infection starts in nose or throat. Many people are asymptomatic carriers (have no symptoms) • Not highly contagious, but spreads through close, direct contact: children in day care more at risk • Local infections: acute otitis media, acute sinusitis, acute bronchitis, pneumonia • Invasive infections: meningitis, bacteremia, septicemia, endocarditis, septic arthritis, osteomyelitis, peritonitis • Many pneumococci are becoming antibiotic-resistant A recent success story Since routine vaccination of infants began in 2005: 94% decrease in invasive disease in children < 2 years old Indirect effect: decreased exposure has led to a 91% decrease in invasive disease in the elderly © 2010 Canadian Paediatric Society I www.cps.ca

  39. Pneumococcal vaccine • Two types available: polysaccharide and conjugate • Polysaccharide: not effective in children < 2 years of age. Used in older children, teens and adults. Contains the 23 serotypes that cause > 90% of serious infections • Conjugate: approved in 2001. Effective at 2 months of age. Contains • 7 serotypes. Vaccines containing 10 and 13 serotypes were recently licensed in Canada and have replaced the 7-serotype vaccine in some jurisdictions • Vaccines have dramatically reduced local and invasive forms of infections in all age groups • Strains that cause serious infections reduced by 40-50% • Local reactions: redness, swelling, pain and tenderness at injection site in • 10-20% of people • Only contraindication: an anaphylactic or other serious allergic reaction to a previous dose of the vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  40. Meningococcal disease • Neisseria meningitides:cancause meningitis, bacteremia, septicemia and other invasive infections • Before vaccine, 200-400 cases of invasive infection/year in Canada, with 20-40 deaths. Since 2001, rate in Canada has decreased, to about 200 cases/year • People with certain chronic diseases are at higher risk • Death from serious disease in 5% of cases, even with treatment, and can occur within 6-12 hours of first signs of illness • Meningococcal bacteria are fragile and infections are not very contagious • Most spread occurs via healthy carriers—about 1 in 5 adolescents and adults—by close, direct contact with mouth secretions, respiratory droplets • 5 serogroups (A, B, C, Y, and W135) cause nearly all infections in Canada, with Groups B and C causing the most illness • Infections caused by serogroups A, B, Y, and W135 will likely drop, now that conjugate quadrivalent vaccine (MCV4) is available in Canada © 2010 Canadian Paediatric Society I www.cps.ca

  41. Meningococcal vaccine • A routine booster dose of either conjugate C or MCV4 is recommended for all children at about age 12 • More frequent boosters may be needed for people at higher risk of meningococcal infections • There is no vaccine available against type B meningococcus • Mild local reactions (redness, swelling, pain or tenderness at the infection site) reported for all vaccine types in 10-20% of people • Only contraindication is an anaphylactic or other serious allergic reaction to a previous dose of the vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  42. Measles • Severe viral infection. Causes high fever, runny nose, cough, conjunctivitis, rash of 1-2 weeks. Pneumonia is common (1-6% of cases) • Encephalitis: 1 in 1,000 cases, can lead to brain damage or death • Rare cases: SSPE (subacutesclerosingpanencephalitis) • Highly contagious: Spreads by direct contact and through the air. Germs become airborne in a cough or sneeze • Before vaccine: large epidemics every 2-3 years. Most children had measles, usually by 18 years of age • 300,000 cases/year in Canada, with 300 deaths and 300 children with brain damage • Vaccine approved in 1963; two-dose schedule in 1996-97 • 2001-06: fewer than 20 cases/year • 2007 outbreak in Quebec: 95 cases, almost all in persons who refused vaccination • 2008 outbreak in Ontario: in over 50 cases, most had received only one dose of vaccine or had never been vaccinated © 2010 Canadian Paediatric Society I www.cps.ca

  43. Measles vaccine • Live, attenuated (weakened) virus • Given with mumps and rubella vaccines as MMR or with varicella as MMR-V • 2 doses required, since about 5% of vaccinated children remain unprotected after first dose • Mild side effects: fever (in 5-10% of children) or rash (in 2% of children) • Severe adverse events rare: risk of encephalitis is less than 1 case per one million doses • Noevidence of links to other diseases/disorders (such as autism, developmental delay, Crohn’s disease, ulcerative colitis) • Contraindications: • Allergic reaction to neomycin, gelatin, or a previous dose of the vaccine • Certain immune system disorders • Pregnancy • Precautions: • Delay vaccine for moderate to severe illness • Delay vaccine for 3 months or more for anyone who has received blood products, as the vaccine may not work © 2010 Canadian Paediatric Society I www.cps.ca

  44. Mumps • Viral infection that can cause fever, headache and swelling of salivary glands around the jaw and cheeks • Can also cause a mild form of meningitis (in 1 in 10 cases) or severe encephalitis, leading to brain damage • Complications: deafness, swelling of testicles, infection of ovaries and (rarely) sterility • Virus in mouth and nose secretions spreads easily by close, direct contact and in droplets from a cough or sneeze • Before vaccine, over 30,000 cases/year reported in Canada • Vaccination programs began in the 1970s • Cases dropped to < 400/year with one-dose schedule, and to an average • 79 cases/year in 2000-06, with a two-dose schedule • Increasing numbers of cases in adolescents and young adults since 2007 may reflect waning immunity after single dose of vaccine © 2010 Canadian Paediatric Society I www.cps.ca

  45. Mumps vaccine • Live, attenuated virus • Given in combination with measles and rubella vaccines as MMR or with varicella as MMR-V: 2 doses • Side effects are rare: Meningitis reported to occur in 1 case per 800,000 doses • Contraindications: • Allergic reaction to neomycin, gelatin, or a previous dose of the vaccine • Certain immune system disorders • Pregnancy • Precautions: • Delay vaccine for moderate to severe illness • Delay vaccine for 3 months or more for anyone who has received blood products, as the vaccine may not work © 2010 Canadian Paediatric Society I www.cps.ca

  46. Rubella • Viral infection, also known as German measles • Can lead to fever, sore throat, swollen glands, rash • Usually mild in children. More severe in teens and adults: arthralgias, arthritis are common in adults • In pregnancy, can infect the fetus, causing severe disabilities: congenital rubella syndrome (CRS), which can result in heart disease, deafness, cataracts, mental retardation • Spreads by direct contact with mouth or nose secretions and droplets from a cough or sneeze. Less contagious than chickenpox or measles • Before vaccine, 85% of children had rubella by age 20: 250,000 cases/year, with 200 cases of congenital rubella syndrome • Worldwide epidemic in 1964: In U.S., ~30,000 babies infected during first • 20 weeks of pregnancy. Of those, ~20,000 cases of CRS and 8,000 deaths • Since routine immunization began in 1980: Only 0-3 babies with CRS are born in Canada each year to unvaccinated mothers © 2010 Canadian Paediatric Society I www.cps.ca

  47. Rubella vaccine • Live, attenuated virus • Given to infants with measles and mumps vaccines as MMR or with varicella as MMR-V: 2 doses • Contraindications: • Allergic reaction to neomycin, gelatin, or a previous dose of vaccine • Certain immune system disorders • Pregnancy • Precautions: • Delay vaccine for moderate to severe illness • Delay vaccine for 3 months or more for anyone who has received blood products, as the vaccine may not work © 2010 Canadian Paediatric Society I www.cps.ca

  48. Rubella vaccine and pregnancy • Women of child-bearing age should be tested for immunity to rubella before first pregnancy • Women not immune and not pregnant should be vaccinated • If pregnant and not immune, delay vaccine, but mother should be vaccinated as soon as possible after delivery for future protection • Side effects of vaccine rare in infants • 25% of vaccinated women experience joint pain © 2010 Canadian Paediatric Society I www.cps.ca

  49. Varicella (chickenpox) • Caused by varicella-zoster virus • Fever, headache, aches and pains, and itchy rash • Usually a mild (but costly) disease: Parents often stay home for 3 days; 30-65% of children are brought to a clinic or hospital • Can lead to complications such as pneumonia, bacteremia, or severe skin infections • Illness is more severe, and complications more common, in teenagers and adults • Severe cases can pose serious health risks, especially for newborn babies, adults, or anyone with a weakened immune system • Highly contagious: Viruses from the throat and scratched skin lesions spread easily through the air. Also spreads by contact with rash • Contagious 2 days before rash appears until the last blister has crusted—usually about 5 days after rash begins • Virus remains dormant in the nervous system and can be reactivated later to cause shingles (zoster) A recent success story Before vaccine > 300,000 cases/year (95% of Canadians got chickenpox) Number of children hospitalized with varicella has dropped dramatically since vaccination programs began. By 2007, an 84% reduction in hospitalizations in provinces/territories with early (2000-02) programs; a 65% reduction for later (2004-06) programs © 2010 Canadian Paediatric Society I www.cps.ca

  50. Varicella vaccine • Live, attenuated virus • 85-90% effective in preventing chickenpox and 100% effective in preventing moderate to severe disease • 2 doses of vaccine now recommended for all children > one year of age (previously, 2 doses given only to people vaccinated at ≥ 13 years of age) • Duration of protection at least 20 years—possibly lifelong • Mild local reactions in about 20% of children • Vaccine-modified disease does occur but is uncommon, and the illness less severe • Transmission of vaccine virus from healthy vaccinated children to susceptible contacts is rare • Given as varicella vaccine or in combination as MMR-V • Contraindications: • Allergic reaction to neomycin or gelatin, or to a previous dose of the vaccine • Certain immune system disorders • Pregnancy • Precautions: • Delay vaccine for moderate to severe illness • Delay vaccine for 3 months or more for anyone who has received blood products, as the vaccine may not work © 2010 Canadian Paediatric Society I www.cps.ca

More Related